The Last Mile: Collaborating to Keep Micromobility Rolling in 2021

 

Like most markets, the first half of 2020 proved a bumpy ride for the micromobility sector. But through resiliency and collaboration, many industry players closed out the year fielding more demand than ever for sustainable and sharable vehicle systems. Across hardware and software, working together will pave the road for a successful 2021. In this podcast, Tony Ho, VP of Global Business Development for Segway, and Vince Cifani, CEO and Founder of micromobility SaaS platform Joyride, speak about the impact COVID-19 had on the industry, and how their companies’ collaborative efforts will ultimately improve micromoiblity for end-users.

In the US, the pandemic found its roots in March of 2020, but Ho says Segway felt the concerns right from the start of the year due to China’s supply chain relationships. “We were very worried about a supply shock,” Ho says. “That turned into a demand shock instead.” The supply chain eventually returned to normal levels, but Ho notes that lockdowns in various areas affected people’s ability to go places, making micromobility transportation options attractive alternatives to public transit. “On the second half of 2020, we saw a lot of crazy demand for our scooters and other form factors as well.”

Cifani recognizes the challenges brought on by the pandemic but says the most significant industry obstacles for scooter-sharing operators actually existed pre-pandemic: Affordable insurance for fleets, vehicle selection and fulfillment, and how to maintain and operate their fleets properly. “Through collaboration with industry leaders like Segway, we’re resolving these challenges for businesses that operate on our software platform,” Cifani says.

Ho and Cifani believe 2021 will be an important year for collaboration in the micromobility industry, both from a technology level and an intercompany. Ho says companies within the industry are more specialized now and that requires collaboration between other specialized companies. “People see the need to focus, but at the same time, they see the need to efficiently work together,” Ho says.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More